Journal Article

Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus

Atsuhiro Ichihara, Matsuhiko Hayashi, Munekazu Ryuzaki, Michiko Handa, Tomohiro Furukawa and Takao Saruta

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue 8, pages 1513-1517
Published in print August 2002 | ISSN: 0931-0509
Published online August 2002 | e-ISSN: 1460-2385 | DOI:
Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus

Show Summary Details


Background. Arterial stiffness assessed by pulse wave velocity (PWV) predicts all‐cause and cardiovascular mortality in diabetic patients with end‐stage renal disease. We studied the preventive effects of a 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on arterial PWV values in this population.

Methods. Twenty‐two patients with normal serum lipid levels received fluvastatin (20 mg/day p.o.) or a placebo for 6 months. Their serum lipid levels, serum levels of C‐reactive protein (CRP), arterial PWV, and ankle brachial indexes (ABI) were determined before, and 3 and 6 months after taking the medication to evaluate arterial stiffness.

Results. At the beginning of the follow‐up, there were no differences in age, blood pressure, body mass index, serum haemoglobin A1c level, serum CRP level, serum lipid levels, PWV or ABI between the placebo‐ (n=10) and the fluvastatin‐treated patients (n=12). After 6 months, the PWV and the serum oxidized low‐density lipoprotein cholesterol (LDL‐C) level increased significantly (from 1969±140 to 2326±190 cm/s and 70.4±13.8 to 91.8±15.5 U/l, respectively) in the placebo‐treated patients. However, the fluvastatin group had a significantly reduced PWV (from 1991±162 to 1709±134 cm/s), oxidized LDL‐C serum levels (from 89.0±9.6 to 73.0±5.8 U/l) and CRP serum levels (from 0.97±0.32 to 0.26±0.16 mg/dl) compared with those in the placebo group.

Conclusions. Long‐term administration of fluvastatin prevents further worsening of arterial biomechanics in haemodialysis patients with type 2 diabetes mellitus, even in the presence of serum lipid levels in the normal range.

Keywords: ankle brachial index; end‐stage renal disease; HMG‐CoA reductase inhibitor; oxidized low‐density lipoprotein; pulse wave velocity

Journal Article.  3339 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.